Building on this observation, it may be expected that GPR35 agonists would have the desirable effect of preventing the prolonged activation of nociceptors associated with visceral hypersensitivity and chronic pain in diseases such as IBS and IBD without blocking acute abdominal pain arising in response to potentially life-threatening obstruction of the bowel. This evidence concerns the gene GPR35 and inflammatory bowel disease.